CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
利用 T 细胞信号通路优化工程化 T 细胞疗法
英文原题：Exploiting T cell signaling to optimize engineered T cell therapies.
查看英文原题
Exploiting T cell signaling to optimize engineered T cell therapies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
工程化 T 细胞疗法，主要为嵌合抗原受体（CAR）-T 和 T 细胞受体（TCR）-T，已成为癌症治疗的新前沿。CAR-T 和 TCR-T 疗法在诸多方面存在差异，包括细胞持久性和毒性，从而导致不同的治疗结局。TCR 和 CAR 均能识别抗原并触发 T 细胞介导的抗肿瘤反应，但它们具有不同的分子结构和信号传导特性。TCR 是最复杂的受体之一，而 CAR 是一种单链嵌合体，整合了来自多种免疫受体的模块。理解这两种系统优势与局限背后的机制，可为下一代 T 细胞疗法的开发铺平道路。本综述综合了关于 TCR 和 CAR 信号传导的最新发现，并重点阐述了通过信号精细调控进行 T 细胞工程的潜在策略。
展开英文摘要原文
Engineered T cell therapies, mainly chimeric antigen receptor (CAR)-T and T cell receptor (TCR)-T, have become the new frontier of cancer treatment. CAR-T and TCR-T therapies differ in many aspects, including cell persistence and toxicity, leading to different therapeutic outcomes. Both TCR and CAR recognize antigens and trigger T cell mediated antitumor response, but they have distinct molecular structures and signaling properties.
TCR represents one of the most complex receptors, while CAR is a single-chain chimera integrating modules from multiple immune receptors. Understanding the mechanisms underlying the strengths and limitations of both systems can pave the way for the development of next-generation T cell therapy. This review synthesizes recent findings on TCR and CAR signaling and highlights the potential strategies of T cell engineering by signaling refinement.
论文信息
- 作者
- Wang H、Song X、Shen L、Wang X、Xu C
- 第一作者单位
- School of Life Science and Technology, ShanghaiTech University, Shanghai, China; Shanghai Clinical Research and Trial Center, Shanghai, China. Electronic address: wanghp@shanghaitech.edu.cn.China
- 通讯作者单位
- State Key Laboratory of Molecular Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China; School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China. Electronic address: cqxu@sibcb.ac.cn.China
- 文献类型
- 非美国政府资助研究 · 综述
- 期刊
- Trends in cancer2022 Feb
- 原文标识
- PubMed 34810156 · DOI 10.1016/j.trecan.2021.10.007